Washington, DC (June 30, 2021) – A new report released by Alliance for Cell Therapy Now, an independent, non-profit organization guided by leaders representing academic and medical institutions, industry innovators, and patients, summarizes the more than 850 clinical studies that are now underway to treat cancer, as well as musculoskeletal, neurological, and cardiovascular conditions, as well as COVID-19.
Ninety-seven percent of all active U.S. clinical trials are either Phase 1 or Phase 2 trials. Similarly, 94 percent of the 130 active U.S. clinical trials exploring the use of MSCs are either Phase 1 or Phase 2 trials.
While results of early clinical studies are promising, the primary barrier to advancing such therapies is the significant cost of conducting large-scale, randomized clinical trials, which are a precursor to bringing safe and effective therapies to patients. The financial barriers are particularly problematic for academic and research institutions, as well as small biotechnology companies, who are responsible for the vast majority of clinical trials investigating the use of RMCTs in the United States. Federal funding is urgently needed to bring safe and effective therapies to patients in need.
About Alliance for Cell Therapy Now
Alliance for Cell Therapy Now (ACT Now) is an independent, non-profit organization guided by leaders representing academic and medical institutions, industry innovators, and patients, that is working to advance safe and effective regenerative medicine and cell therapies for patients in need. See www.allianceforcelltherapynow.org